

CORRECTION

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

In the article “CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients” by L.A. Lieberman et al.,¹ there are errors in table 1 and figure 3. In table 1, the number of samples reported missed the inclusion of an additional 51 longitudinal NTZ control samples (34 STRATA and 17 non-STRATA) from a serial collection. In figure 3, there is a discrepancy in the assignment of the “at diagnosis” PML samples (red circles). All calculations were performed on the correct data, so neither of these errors affects the conclusions of the manuscript. Corrected versions of both are below. The authors regret the error.

REFERENCE

1. Lieberman LA, Zeng W, Singh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. *Neurology* 2016;86:375–381.

Table 1 Patient demographics

	All samples			STRATA			Non-STRATA			
	NTZ ctrl	Pre-PML	PML	NTZ ctrl	Pre-PML, no at Dx	Pre-PML + PML at Dx	PML at Dx only	NTZ ctrl	Pre-PML	PML
No. of patients	104	9	21 ^a	55	2	7	1	49	0	11
No. of samples (patients)	155	17	21	89	17 (9 ^a)	9 (8 ^b)		66	0	12
Age, y										
Mean ± SD	44.6 ± 7.96	42 ± 5.65	44.6 ± 7.32	42.4 ± 7.66	42 ± 5.65	42.4 ± 7.77		47.1 ± 7.62	NA	46 ± 7.39
Sex										
% Female	77.9	66.7	84.2	78.2	66.7	75		77.6	NA	90.1
No. of NTZ doses										
Mean ± SD	63 ± 17.13	52 ± 5.57	64 ± 13.89	50 ± 8.41	52 ± 5.57	70 ± 15.74		77 ± 13.25	NA	59 ± 10.59

Abbreviations: NA = not available; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy.

^aWe do not have at diagnosis samples for 2 of these patients.

^bOne patient with PML has 2 samples within 1 month of diagnosis.

Figure 3

